Evidence map›Paper›PMID 40954414›Full record

ArticleMolecular imaging and biology2025

Development of New NanoAlbumin-based Radiotracers: Preclinical Evaluation Of [

Vijayaraj Kuniyil Kulangara, Aida Mary Abreu Diaz, Sara M Elkashef, Miriam Ruiz Pena, Mariia Kiseleva, Samila Leon Chaviano, Yat Hei Leung, Indranil Nandi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vijayaraj Kuniyil KulangaraResearch and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada. Vijaya.kk@jubl.com.
Aida Mary Abreu Diaz *Research and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.
Sara M Elkashef *Research and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.
Miriam Ruiz PenaResearch and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.
Mariia KiselevaResearch and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.
Samila Leon ChavianoResearch and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.
Yat Hei LeungResearch and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.
Indranil NandiResearch and Development, Jubilant DraxImage Inc. dba Jubilant Radiopharma, Kirkland, Québec, H9H 4J4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSentinel lymph node (SLN) mapping is a critical procedure in the staging and treatment of cancers, such as breast cancer and melanoma. Current radiocolloids used in SLN localization, like [

methodsNanoalbumin radiotracers were prepared by thermal denaturation of human serum albumin (HSA), followed by conjugation with 2,2',2″,2″'-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) and labeling with gallium-68. The stability of [

results[

conclusion[

Indexed as

Gallium RadioisotopesHeterocyclic Compounds, 1-RingNanoparticlesRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansMicePositron Emission Tomography Computed TomographyRadioactive TracersTissue Distribution1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidGallium RadioisotopesHeterocyclic Compounds, 1-RingRadioactive TracersRadiopharmaceuticals[68Ga]Ga-DOTA-nanoHSANanoparticlesPET/CT imagingSentinel lymph nodeSLN mapping

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.